Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors

Abstract The organoid approach preserves the intricate molecular and genetic characteristics of tumor tissues, playing a pivotal role in advancing precision oncology. This preservation enables the exploration of cancer therapies and in vitro validation of drug efficacy. Organoids have emerged as ind...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoting Wang, Danyan Lin, Ninghan Feng
Format: Article
Language:English
Published: BMC 2025-07-01
Series:World Journal of Surgical Oncology
Subjects:
Online Access:https://doi.org/10.1186/s12957-025-03948-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343650708848640
author Xiaoting Wang
Danyan Lin
Ninghan Feng
author_facet Xiaoting Wang
Danyan Lin
Ninghan Feng
author_sort Xiaoting Wang
collection DOAJ
description Abstract The organoid approach preserves the intricate molecular and genetic characteristics of tumor tissues, playing a pivotal role in advancing precision oncology. This preservation enables the exploration of cancer therapies and in vitro validation of drug efficacy. Organoids have emerged as indispensable tools in the study of urological cancers, facilitating research on tumorigenesis, drug testing, and the development of therapeutic combinations. Their superiority over traditional 2D cell cultures and patient-derived xenograft (PDX) models lies in their enhanced ability to more accurately replicate the in vivo environment. Modern organoid platforms integrate 3D bioprinting, co-culture systems, microfluidics, and artificial intelligence to significantly improve the precision, scalability, and efficiency of cancer research. These integrated systems serve as powerful analytical tools, propelling the development of personalized therapies for urological malignancies. This article provides a comprehensive review of the establishment and potential of organoid technologies in treating the three major urogenital system cancers—prostate, bladder, and renal—highlighting their trajectory from basic research to clinical applications and their expanding synergy with bioengineering innovations. Graphical Abstract Organoids serve as a bridge between preclinical models and personalized therapies, providing a key preclinical model for addressing urological tumors.
format Article
id doaj-art-8b86df30f7a4404ba59c8180a7f78b39
institution Kabale University
issn 1477-7819
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series World Journal of Surgical Oncology
spelling doaj-art-8b86df30f7a4404ba59c8180a7f78b392025-08-20T03:42:53ZengBMCWorld Journal of Surgical Oncology1477-78192025-07-0123111610.1186/s12957-025-03948-2Harnessing organoid technology in urological cancer: advances and applications in urinary system tumorsXiaoting Wang0Danyan Lin1Ninghan Feng2Department of Urology, Jiangnan University Medical Center (Wuxi No. 2, People’s Hospital)Wuxi School of Medicine, Jiangnan UniversityDepartment of Urology, Jiangnan University Medical Center (Wuxi No. 2, People’s Hospital)Abstract The organoid approach preserves the intricate molecular and genetic characteristics of tumor tissues, playing a pivotal role in advancing precision oncology. This preservation enables the exploration of cancer therapies and in vitro validation of drug efficacy. Organoids have emerged as indispensable tools in the study of urological cancers, facilitating research on tumorigenesis, drug testing, and the development of therapeutic combinations. Their superiority over traditional 2D cell cultures and patient-derived xenograft (PDX) models lies in their enhanced ability to more accurately replicate the in vivo environment. Modern organoid platforms integrate 3D bioprinting, co-culture systems, microfluidics, and artificial intelligence to significantly improve the precision, scalability, and efficiency of cancer research. These integrated systems serve as powerful analytical tools, propelling the development of personalized therapies for urological malignancies. This article provides a comprehensive review of the establishment and potential of organoid technologies in treating the three major urogenital system cancers—prostate, bladder, and renal—highlighting their trajectory from basic research to clinical applications and their expanding synergy with bioengineering innovations. Graphical Abstract Organoids serve as a bridge between preclinical models and personalized therapies, providing a key preclinical model for addressing urological tumors.https://doi.org/10.1186/s12957-025-03948-2OrganoidsUrinary system tumorsDrug screeningPrecision medicine3D culture
spellingShingle Xiaoting Wang
Danyan Lin
Ninghan Feng
Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
World Journal of Surgical Oncology
Organoids
Urinary system tumors
Drug screening
Precision medicine
3D culture
title Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
title_full Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
title_fullStr Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
title_full_unstemmed Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
title_short Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors
title_sort harnessing organoid technology in urological cancer advances and applications in urinary system tumors
topic Organoids
Urinary system tumors
Drug screening
Precision medicine
3D culture
url https://doi.org/10.1186/s12957-025-03948-2
work_keys_str_mv AT xiaotingwang harnessingorganoidtechnologyinurologicalcanceradvancesandapplicationsinurinarysystemtumors
AT danyanlin harnessingorganoidtechnologyinurologicalcanceradvancesandapplicationsinurinarysystemtumors
AT ninghanfeng harnessingorganoidtechnologyinurologicalcanceradvancesandapplicationsinurinarysystemtumors